Current concepts in the management of Helicobacter pylori infection:: the maastricht III consensus report

被引:1423
作者
Malfertheiner, P.
Megraud, F.
O'Morain, C.
Bazzoli, F.
El-Omar, E.
Graham, D.
Hunt, R.
Rokkas, T.
Vakil, N.
Kuipers, E. J.
机构
[1] Univ Magdeburg, Fak Med, Zentrum Innere Med, Klin Gastroenterol Hepatol & Infektiol, D-39120 Magdeburg, Germany
[2] INSERM, U853, Bordeaux, France
[3] Univ Dublin Trinity Coll, Adelaide & Meath Hosp, Dublin, Ireland
[4] Univ Bologna, Bologna, Italy
[5] Univ Aberdeen, Aberdeen AB9 1FX, Scotland
[6] VA Med Ctr, Houston, TX USA
[7] McMaster Univ, Hamilton, ON, Canada
[8] Henry Dunant Hosp, Athens, Greece
[9] Univ Wisconsin, Sch Med, Milwaukee, WI 53201 USA
[10] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
关键词
D O I
10.1136/gut.2006.101634
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Guidelines on the management of Helicobacter pylori, which cover indications for management and treatment strategies, were produced in 2000. Aims: To update the guidelines at the European Helicobacter Study Group (EHSG) Third Maastricht Consensus Conference, with emphasis on the potential of H pylori eradication for the prevention of gastric cancer. Results: Eradication of H pylori infection is recommended in (a) patients with gastroduodenal diseases such as peptic ulcer disease and low grade gastric, mucosa associated lymphoid tissue (MALT) lymphoma; (b) patients with atrophic gastritis; (c) first degree relatives of patients with gastric cancer; (d) patients with unexplained iron deficiency anaemia; and (e) patients with chronic idiopathic thrombocytopenic purpura. Recurrent abdominal pain in children is not an indication for a "test and treat'' strategy if other causes are excluded. Eradication of H pylori infection (a) does not cause gastro-oesophageal reflux disease (GORD) or exacerbate GORD, and (b) may prevent peptic ulcer in patients who are naive users of non-steroidal antiinflammatory drugs (NSAIDs). H pylori eradication is less effective than proton pump inhibitor (PPI) treatment in preventing ulcer recurrence in long term NSAID users. In primary care a test and treat strategy using a non-invasive test is recommended in adult patients with persistent dyspepsia under the age of 45. The urea breath test, stool antigen tests, and serological kits with a high accuracy are non-invasive tests which should be used for the diagnosis of H pylori infection. Triple therapy using a PPI with clarithromycin and amoxicillin or metronidazole given twice daily remains the recommended first choice treatment. Bismuth-containing quadruple therapy, if available, is also a first choice treatment option. Rescue treatment should be based on antimicrobial susceptibility. Conclusion: The global burden of gastric cancer is considerable but varies geographically. Eradication of H pylori infection has the potential to reduce the risk of gastric cancer development.
引用
收藏
页码:772 / 781
页数:10
相关论文
共 100 条
[21]  
Drumm Brendan, 2000, JPGN, V30, P207, DOI 10.1097/00005176-200002000-00020
[22]   Iron-deficiency anemia and Helicobaeter pylori infection:: A review of the evidence [J].
DuBois, S ;
Kearney, DJ .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (02) :453-459
[23]   Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection [J].
Ekström, AM ;
Held, M ;
Hansson, L ;
Engstrand, L ;
Nyrén, O .
GASTROENTEROLOGY, 2001, 121 (04) :784-791
[24]   Interleukin-1 polymorphisms associated with increased risk of gastric cancer [J].
El-Omar, EM ;
Carrington, M ;
Chow, WH ;
McColl, KEL ;
Bream, JH ;
Young, HA ;
Herrera, J ;
Lissowska, J ;
Yuan, CC ;
Rothman, N ;
Lanyon, G ;
Martin, M ;
Fraumeni, JF ;
Rabkin, CS .
NATURE, 2000, 404 (6776) :398-402
[25]   Meta-analysis:: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies [J].
Fischbach, LA ;
Van Zanten, SV ;
Dickason, J .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (10) :1071-1082
[26]   Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy:: experience from a large prospective series [J].
Fischbach, W ;
Goebeler-Kolve, ME ;
Dragosics, B ;
Greiner, A ;
Stolte, M .
GUT, 2004, 53 (01) :34-37
[27]   Primary gastric B-cell lymphoma:: Results of a prospective multicenter study [J].
Fischbach, W ;
Dragosics, B ;
Kolve-Goebeler, ME ;
Ohmann, C ;
Greiner, A ;
Yang, Q ;
Böhm, S ;
Verreet, P ;
Horstmann, O ;
Busch, M ;
Dühmke, E ;
Müller-Hermelink, HK ;
Wilms, K .
GASTROENTEROLOGY, 2000, 119 (05) :1191-1202
[28]   Helicobacter pylori infection and immune thrombocytopenic purpura:: An update [J].
Franchini, M ;
Veneri, D .
HELICOBACTER, 2004, 9 (04) :342-346
[29]   Helicobacter pylori-associated immune thrombocytopenia [J].
Franchini, M ;
Veneri, D .
PLATELETS, 2006, 17 (02) :71-77
[30]   Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura?: Analysis of 207 eradicated chronic ITP cases in Japan [J].
Fujimura, K ;
Kuwana, M ;
Kurata, Y ;
Imamura, M ;
Harada, H ;
Sakamaki, H ;
Teramura, M ;
Koda, K ;
Nomura, S ;
Sugihara, S ;
Shimomura, T ;
Fujimoto, TT ;
Oyashiki, K ;
Ikeda, Y .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2005, 81 (02) :162-168